Media Summary: Dr. Kamau Pierre, with the Translational Disease Modeling Group at Sanofi, discusses how Quantitaive Systems Pharmacology ... Professor Jason E. Farley, Associate Professor and Director of The REACH Initiative of The Johns Hopkins School of Nursing, ... Dr. Hoai-Thu Thai with Sanofi explains how MIDD was used to support isatuximab (Sarclisa) dosing regimen selection in ...
Module 7 Case Study 7 - Detailed Analysis & Overview
Dr. Kamau Pierre, with the Translational Disease Modeling Group at Sanofi, discusses how Quantitaive Systems Pharmacology ... Professor Jason E. Farley, Associate Professor and Director of The REACH Initiative of The Johns Hopkins School of Nursing, ... Dr. Hoai-Thu Thai with Sanofi explains how MIDD was used to support isatuximab (Sarclisa) dosing regimen selection in ... Dr. Pascal Chanu talks about how MIDD is used to optimize a pediatric program. The drug discussed is CERA, which stands for ... Dr. Binfeng Xia with Sanofi U.S. shows how Physiologically Based Pharmokinetic (PBPK) models were used to support Eliglustat ... Dr. Dinko Rekic of Astra-Zeneca shows how the FDA MIDD Pilot Program enabled a Phase 2 trial start prior to multiple standing ...
Hello guys this is michael maxx finishing up our our class aep859 with my
